China SXT Pharmaceuticals (SXTC) Retained Earnings (2018 - 2025)

China SXT Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at -$34.4 million for Q3 2025.

• In Q3 2025, Retained Earnings fell 34.76% year-over-year to -$34.4 million; the TTM figure through Sep 2025 stood at -$34.4 million (down 34.76% YoY), while the FY2025 annual figure was -$28.0 million, down 13.37% from the prior year.
• Retained Earnings was -$34.4 million for Q3 2025 at China SXT Pharmaceuticals, down from -$28.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $956142.0 in Q1 2022 to a low of -$34.4 million in Q3 2025.
• Historically, Retained Earnings has averaged -$19.4 million across 5 years, with a median of -$23.2 million in 2023.
• Biggest YoY gain for Retained Earnings was 189.36% in 2021; the steepest drop was 27210.06% in 2021.
• A 5-year view of Retained Earnings shows it stood at -$13.0 million in 2021, then tumbled by 31.73% to -$17.2 million in 2022, then plunged by 82.21% to -$31.3 million in 2023, then climbed by 18.51% to -$25.5 million in 2024, then slumped by 34.76% to -$34.4 million in 2025.
• The last three Retained Earnings figures came in at -$34.4 million (Q3 2025), -$28.0 million (Q1 2025), and -$25.5 million (Q3 2024), per Business Quant data.